Vitamin B6 (Pyridoxal Phosphate)
For informational purposes only — not medical advice. Always consult a qualified healthcare provider before making changes to your health regimen. Full disclaimer →
- PLP is required to synthesize every major mood-regulating neurotransmitter — serotonin, dopamine, norepinephrine, and GABA. Tryptophan hydroxylase (serotonin synthesis), DOPA decarboxylase (dopamine synthesis), and glutamate decarboxylase (GABA synthesis) all require PLP as a coenzyme. Suboptimal B6 impairs production across all these pathways simultaneously, explaining the well-documented associations between low B6 and depression, anxiety, and cognitive symptoms — independent of other nutritional factors.
- Vitamin B6 is one of three essential vitamins for homocysteine clearance, alongside B12 and folate. The transsulfuration pathway converts homocysteine to cystathionine via the enzyme cystathionine beta-synthase — a PLP-dependent reaction. When B6 is deficient, this step is impaired, elevating homocysteine even if B12 and folate are adequate. Homocysteine predicts cardiovascular events and dementia independently of other risk factors, making B6 an important co-target in cardiovascular prevention alongside B12 and folate.
- Chronic inflammation degrades PLP — making B6 deficiency common in people with elevated hsCRP, regardless of dietary intake. Inflammatory cytokines accelerate the conversion of PLP to pyridoxic acid (an inactive metabolite), reducing functional B6 availability. People with chronic inflammatory conditions — rheumatoid arthritis, IBD, obesity, metabolic syndrome — have systematically lower PLP despite normal dietary intake. This inflammation-driven B6 depletion creates a bidirectional relationship: low B6 may worsen inflammation by impairing immune cell function, while inflammation depletes B6 further.
- Oral contraceptive use is one of the most common causes of B6 deficiency in premenopausal women. Estrogen-containing contraceptives increase tryptophan catabolism via the kynurenine pathway, increasing the demand for PLP and accelerating its depletion. Women on OCPs have significantly lower plasma PLP levels on average, and B6 supplementation has been shown to reverse the depressive symptoms and mood changes that some women experience on hormonal contraceptives.
- High-dose B6 supplementation produces peripheral neuropathy — the only water-soluble vitamin with documented toxicity. Unlike most B vitamins, pyridoxine at chronically high doses (typically above 50–100 mg/day for months to years, though some cases reported at lower doses) causes sensory peripheral neuropathy — numbness, tingling, and pain in the extremities. Symptoms are often reversible on discontinuation but may persist. Standard multivitamins with 1–4 mg/day of B6 are safe. Testing PLP before supplementing allows appropriate dose targeting.
The Neurotransmitter Coenzyme: Why B6 Deficiency Affects Mood, Cognition, and Heart Health Simultaneously
Vitamin B6 as PLP is involved in so many metabolic pathways that its deficiency produces effects across organ systems that seem unrelated until the common underlying mechanism is understood. Mood dysregulation, cognitive slowing, elevated homocysteine, and hypochromic microcytic anemia — all attributable to PLP deficiency — stem from the same root cause: the failure of a single coenzyme that underpins dozens of enzymatic reactions simultaneously.
The neurotransmitter synthesis pathway alone involves multiple PLP-dependent steps. Serotonin synthesis from tryptophan requires PLP at the aromatic L-amino acid decarboxylase step. Dopamine synthesis from DOPA requires the same enzyme. GABA synthesis from glutamate requires glutamate decarboxylase — also PLP-dependent. When PLP is insufficient, all of these pathways are impaired concurrently. The resulting neurotransmitter depletion across serotonin, dopamine, and GABA simultaneously explains the clinical picture of B6 deficiency: depressed mood, anxiety, irritability, and cognitive fog occurring together. 1
Who Is at Risk for B6 Suboptimality
B6 suboptimality is not confined to people with severe malnutrition. The following groups carry meaningfully elevated risk of functional B6 insufficiency:
Women on oral contraceptives: Estrogen increases tryptophan catabolism through the kynurenine pathway, substantially increasing PLP demand. Studies consistently find lower plasma PLP in OCP users compared to non-users, and B6 supplementation (typically 50–100 mg/day) reverses the mood and cognitive changes that a subset of women experience on hormonal contraceptives.
People with chronic inflammation: Elevated inflammatory cytokines accelerate PLP catabolism to pyridoxic acid. CRP is negatively correlated with plasma PLP in population studies — the more inflammation, the lower the B6. This connection means people with metabolic syndrome, obesity, or inflammatory conditions are systematically at higher risk regardless of diet.
Older adults: B6 absorption declines with age, demand increases (particularly for immune function), and the conversion efficiency of dietary pyridoxine to active PLP may decrease. The Hordaland Homocysteine Study found that B6 deficiency was substantially more prevalent in adults over 65.
People taking isoniazid or hydralazine: These medications form inactive complexes with PLP, functionally depleting B6. Peripheral neuropathy from isoniazid treatment is a well-recognized clinical syndrome prevented by concurrent B6 supplementation.
| Serum PLP | Status | Notes |
|---|---|---|
| < 5 ng/mL | Deficient | Clinical deficiency; neuropathy and anemia risk |
| 5–20 ng/mL | Suboptimal | Impaired neurotransmitter synthesis; elevated homocysteine likely |
| 30–100 ng/mL | Longevity optimal | Adequate for all PLP-dependent reactions |
| > 200 ng/mL | Potentially toxic range | Peripheral neuropathy risk; review supplementation dose |
| Range Type | Value (ng/mL) | Notes |
|---|---|---|
| Standard Clinical Range | Serum PLP: 5–50 ng/mL (reference ranges vary by laboratory) | Designed to identify disease risk — not longevity optimisation. |
| Longevity-Optimal Target | 30–100 ng/mL |
Associated with reduced all-cause mortality and extended healthspan.
The standard clinical reference range for PLP has a lower bound of approximately 5 ng/mL — calibrated to prevent overt deficiency disease. Functional suboptimality, with subclinical effects on neurotransmitter synthesis and homocysteine clearance, occurs at levels below 20–30 ng/mL in many individuals. Longevity-focused interpretation targets the 30–100 ng/mL range. Values above 200 ng/mL from excessive supplementation (above 50–100 mg/day of B6 for extended periods) are associated with peripheral sensory neuropathy — a well-documented toxicity of high-dose pyridoxine supplementation. B6 toxicity from food sources alone is not known.
|
Already have your results? See what your Vitamin B6 (Pyridoxal Phosphate) and other markers reveal about your longevity in 60 seconds.
Analyze My Labs →Affiliate disclosure: we may earn a commission if you purchase through these links at no extra cost to you.
Should I test B6 alongside B12 and folate?
Yes — they function as an integrated system for homocysteine metabolism and one-carbon transfer reactions, and deficiency in any one of the three can elevate homocysteine. Testing all three together (B6 + B12 + folate + homocysteine) provides a complete picture of this pathway. If homocysteine is elevated, identifying which vitamin(s) are deficient guides supplementation precisely rather than requiring broad-spectrum B-complex supplementation. B6 deficiency-driven homocysteine elevation is specifically helped by B6 supplementation in the 50–100 mg/day range; B12-driven elevation responds to B12 repletion; folate-driven elevation responds to folate. Testing distinguishes which driver is operative.
What foods are richest in vitamin B6?
Animal protein sources are among the richest B6 foods: beef liver (0.9 mg per 3 oz), tuna (0.9 mg per 3 oz), salmon (0.6 mg per 3 oz), chicken breast (0.5 mg per 3 oz). Plant sources include chickpeas (1.1 mg per cup — among the highest food sources), potatoes (0.6 mg per medium potato), bananas (0.4 mg each), and fortified cereals. The RDA for adults is 1.3 mg/day (1.7 mg for men over 50, 1.5 mg for women over 50). Most people consuming varied diets meet RDA; suboptimal status typically reflects the combination of borderline intake plus increased metabolic demand from inflammation, medications, or genetic variation in B6 metabolism enzymes.
What is the difference between pyridoxine and pyridoxal phosphate supplements?
Pyridoxine hydrochloride is the most common supplemental form — an inexpensive, stable form that must be converted to PLP by the body after absorption. This conversion requires functional liver enzymes. For most people, pyridoxine supplements effectively raise serum PLP. Pyridoxal-5'-phosphate (P-5-P) is the pre-converted, active coenzyme form — theoretically better absorbed and utilized in people with impaired conversion capacity. In practice, for most healthy adults, pyridoxine and P-5-P supplements produce similar serum PLP levels at comparable doses. P-5-P may be preferable for people with liver disease or known conversion inefficiency. The peripheral neuropathy risk from high-dose supplementation applies primarily to pyridoxine at very high doses, not standard dietary or therapeutic doses of either form.
How does B6 status affect dream recall and sleep quality?
Vitamin B6 plays a well-documented role in dream vividness and recall — a phenomenon recognized in sleep research for decades. PLP is required to synthesize serotonin from tryptophan, and serotonin is a precursor to melatonin. More directly, B6 is involved in the conversion of tryptophan to neurotransmitters that modulate REM sleep. Several small studies and widespread anecdotal reports suggest that B6 supplementation increases dream vividness and recall, likely by enhancing serotonin and potentially acetylcholine signaling during REM sleep. While not a clinical indication for B6 testing, this effect is frequently the first subjective sign that B6 status is either improving or elevated from supplementation.